Videos

Chrisandra Shufelt, MD, on using a cardiovascular risk score to guide hormone therapy candidacy at menopause.

Nearly half of menopausal sleep disruption tracks with nighttime hot flashes, while the remainder appears independent, making nocturnal fragmentation a distinct clinical target rather than a secondary effect.

Sleep disturbance is often the most bothersome symptom of the menopause transition, yet it frequently goes unreported unless clinicians ask directly about sleep quality and daytime fatigue.

Susan Reed, MD, on the need for menopause research funding, a clinical trials network, and studies in understudied groups and perimenopause.

Chrisandra Shufelt, MD, on why menopause is a window for cardiovascular prevention and the risk factors OB/GYNs should assess.

Matthew Nudy, MD, on estrogen's cardiovascular effects, risk assessment, and hormone therapy safety in younger menopausal women.

Rhonda Voskuhl, MD, on a case series in which estriol and progesterone improved self-reported cognition in menopausal women at 12 months.

In the premiere episode of Mind, Body, & the Pause, Soma Mandal, MD, is joined by Manisha Parulekar, MD, and Jocelyn Carlo, MD, FACOG, to discuss the stages of the menopause transition.

Jessica Shepherd, MD, MBA, FACOG, joins Missed & Dismissed to discuss why perimenopause is overlooked and how disparities shape who gets care.

Pauline M. Maki, PhD, explains that OPTION-VMS provided reassuring news about the safety of fezolinetant (Veozah): No new or emerging adverse events were evident in the real-world study.

Misread Women’s Health Initiative data sidelined hormone therapy and menopause education, according to Mary Jane Minkin, MD, FACOG.

Susan Reed, MD, on the MsFLASH network's pooled findings, including nonhormonal therapies comparable to low-dose estradiol and CBT for sleep.

Late recurrence, high-risk features, and treatment failure can signal midlife night sweats aren’t menopause, according to Cheryl Cox Kinney, MD.

JoAnn V. Pinkerton, MD, offers primary care counseling on elinzanetant's side effects and the early onset and continued relief of hot flashes.

Menopausal brain fog is common, and hormone therapy has neutral cognitive effects, according to Pauline M. Maki, PhD.

Stephanie S. Faubion, MD, on choosing between fezolinetant and elinzanetant, liver monitoring, follow-up, and open questions in menopause care.

JoAnn V. Pinkerton, MD, MSCP, reviews 4 pooled elinzanetant analyses from OASIS presented at The Menopause Society Annual Meeting 2026, spanning late perimenopause, sleep, VMS reduction, and safety.

Distress, not low libido alone, defines HSDD, which requires a biopsychosocial evaluation, according to Holly N. Thomas, MD, MS.

Open-ended questions help ob-gyns untangle GSM and low desire and build adherence-focused treatment plans, according to Sheryl Kingsberg, PhD.

The investigational Evident test requires 3 tumor markers on the same extracellular vesicle to flag early-stage ovarian cancer.

Real-world fezolinetant (Veozah) sleep data help ob-gyns counsel patients hesitant about hormone therapy, according to Marla Shapiro, CM, MDCM.

Cultural upbringing gives context to sexual dysfunction but does not make the diagnosis, according to Sameena Rahman, MD, FACOG.

Pauline M. Maki, PhD, explains the difference between measuring sleep objectively with actigraphy and asking women to rate their sleep on a questionnaire.

Experts address COVID-19 vaccine myths, safety evidence, and how to frame the benefits of vaccination in pregnancy.

Experts look ahead to new maternal vaccines and how to counsel patients on receiving several in one pregnancy.

Experts discuss common patient concerns about vaccination in pregnancy and strategies to improve uptake.

Experts discuss how obstetric and pediatric clinicians can coordinate to protect newborns.

Experts review ACOG's 2026-27 guidance and the RSV window extension for pregnant and postpartum patients.

Soma Mandal, MD, is launching “Mind, Body, & the Pause: the Perimenopause and Beyond Series” on Contemporary OB/GYN, featuring specialists from across Hackensack Meridian Health.

On September 9, 2026, certolizumab pegol received FDA Breakthrough Therapy Designation for APS pregnancy; Jane E. Salmon, MD, reviews the IMPACT trial results behind it.